NanoKnife vs Stereotactic Radiation for Prostate Cancer

This trial aims to determine if a new treatment, irreversible electroporation (IRE), is as effective as standard radiation therapy for individuals with intermediate-risk prostate cancer. Participants will receive either the IRE treatment or continue with radiation therapy to assess which is more effective. The trial seeks men with prostate cancer that hasn't spread and is in a specific, manageable stage. As a Phase 3 trial, this study represents the final step before potential FDA approval, offering participants the opportunity to contribute to a treatment that could soon become widely available.

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you have a bleeding disorder or cannot safely stop blood thinners for the procedure. Also, you cannot use androgen deprivation therapy during the trial.

Research has shown that irreversible electroporation (IRE) is generally safe for treating prostate cancer. In a recent study using the NanoKnife system, only about 8.3% of patients experienced serious side effects, and none faced more severe issues.

Another study found that patients treated with IRE maintained good urinary and sexual function. However, a less common side effect was the development of rectal fistulas, which are abnormal tissue connections, though these cases were rare.

Irreversible Electroporation (IRE) is unique because it uses electrical pulses to create tiny holes in cancer cell membranes, leading to cell death without significant heat generation. This method contrasts with traditional prostate cancer treatments like surgery, radiation, or hormone therapy, which can damage surrounding healthy tissues. Researchers are excited about IRE because it offers a targeted approach that may reduce side effects and preserve more of the prostate's normal function. Additionally, IRE's minimally invasive nature could lead to quicker recovery times for patients compared to conventional treatments.

This trial will compare Irreversible Electroporation (IRE) with Stereotactic Radiation for treating prostate cancer. Studies have shown that IRE can be quite effective, with 71% of patients having no cancer detected in the treated area 12 months after receiving IRE. This indicates that the treatment successfully targeted and eliminated prostate cancer cells in most patients. Additionally, IRE preserves urinary and sexual functions, greatly benefiting quality of life. Some studies have reported a 100% overall survival rate with IRE, suggesting it is a promising option for treating prostate cancer. Participants in this trial will receive either IRE or Radiation Therapy, allowing for a direct comparison of these treatments.²⁴⁶⁷⁸